Physician profile
David C Cheng
NPI 1124075577
$692.14
in general payments reported to CMS, 2019-2025
16 companies · $22.54 in 2025
The $22.54 reported for 2025 was less than what a typical Emergency Medical Services provider received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $26.04 · 2021: $60.01 · 2022: $86.71 · 2024: $69.42 · 2025: $22.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $91.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $91.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $247.31 | 2019 | |
| Aroa Biosurgery Incorporated | $92.37 | 2019 | |
| Tactile Systems Technology INC | $64.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.59 | 2022 | |
| Glaxosmithkline, LLC. | $35.06 | 2022-2024 | Shingrix |
| Mylan Specialty L.P. | $26.04 | 2020 | |
| Smith+Nephew, INC. | $22.83 | 2019 | |
| Dexcom, INC. | $22.54 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $21.58 | 2021 | |
| Lilly USA, LLC | $20.19 | 2024 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $18.87 | 2024 | Voquezna |
| Amgen INC. | $15.61 | 2024 | Repatha, Otezla |
| Abbvie INC. | $13.47 | 2021 | |
| Novo Nordisk INC | $12.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.05 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.